5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
31
HOLX Quote, Financials, Valuation and Earnings
Last price:
$56.21
Seasonality move
:
2.42%
Day range:
$54.87 - $56.24
52-week range:
$51.90 - $84.67
Dividend yield:
0%
P/E ratio:
23.39x
P/S ratio:
3.20x
P/B ratio:
2.67x
Volume:
12.8M
Avg. volume:
3.6M
1-year change:
-27.16%
Market cap:
$12.4B
Revenue:
$4B
EPS (TTM):
$2.37
Analysts' Opinion
-
Consensus RatingHologic has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 13 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $67.96, Hologic has an estimated upside of 22.61% from its current price of $55.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $60.00 representing -8.25% downside risk from its current price of $55.43.
Fair Value
-
According to the consensus of 15 analysts, Hologic has 22.61% upside to fair value with a price target of $67.96 per share.
HOLX vs. S&P 500
-
Over the past 5 trading days, Hologic has underperformed the S&P 500 by -3.82% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hologic does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hologic revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Hologic reported revenues of $1B.
Earnings Growth
-
Hologic earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Hologic reported earnings per share of -$0.08.
Enterprise value:
13.2B
EV / Invested capital:
1.86x
Price / LTM sales:
3.20x
EV / EBIT:
16.46x
EV / Revenue:
3.29x
PEG ratio (5yr expected):
1.12x
EV / Free cash flow:
13.66x
Price / Operating cash flow:
13.29x
Enterprise value / EBITDA:
12.02x
Gross Profit (TTM):
$2.1B
Return On Assets:
6.32%
Net Income Margin (TTM):
13.83%
Return On Equity:
11.45%
Return On Invested Capital:
7.53%
Operating Margin:
3.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4.1B | $4B | $4B | $1B | $1B | |
| Gross Profit | $2.3B | $2B | $2.1B | $542.3M | $377.3M | |
| Operating Income | $924.5M | $680.7M | $758.5M | $217.4M | $37.9M | |
| EBITDA | $1.4B | $993.4M | $1.1B | $317.5M | $76.8M | |
| Diluted EPS | $2.99 | $1.96 | $2.37 | $0.72 | -$0.08 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.7B | $3.9B | $4.2B | $3.8B | $3.2B | |
| Total Assets | $8B | $9.5B | $9.4B | $8.7B | $8.5B | |
| Current Liabilities | $1B | $1.3B | $955M | $954.6M | $989.7M | |
| Total Liabilities | $4.2B | $4.7B | $4.1B | $3.9B | $3.9B | |
| Total Equity | $3.8B | $4.8B | $5.3B | $4.8B | $4.6B | |
| Total Debt | $2.7B | $3.1B | $2.8B | $2.6B | $2.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $959M | $1.1B | $1.1B | $292.4M | $169.4M | |
| Cash From Investing | -$99.3M | -$237.4M | -$984.6M | -$38.5M | -$324.3M | |
| Cash From Financing | -$573M | -$1.3B | -$899.3M | -$4.2M | -$201.7M | |
| Free Cash Flow | $840.5M | $948.9M | $970.1M | $264.4M | $129.2M | |
HOLX
Sector
Market Cap
$12.4B
$34.5M
Price % of 52-Week High
65.47%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
6.42%
-0.79%
1-Year Price Total Return
-27.16%
-42.08%
Beta (5-Year)
0.544
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$55.91
200-day SMA
Sell
Level
$72.80
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$57.10
Relative Strength Index (RSI14)
Sell
Level
43.96
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-53.5526
50-day SMA
Sell
Level
$59.99
MACD (12, 26)
Sell
Level
-1.63
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.4094)
Buy
CA Score
(Annual)
Level (0.4447)
Buy
Beneish M-Score
(Annual)
Level (-2.7631)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.9721)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Stock Forecast FAQ
In the current month, HOLX has received 2 Buy ratings 13 Hold ratings, and 0 Sell ratings. The HOLX average analyst price target in the past 3 months is $67.96.
-
Where Will Hologic Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hologic share price will rise to $67.96 per share over the next 12 months.
-
What Do Analysts Say About Hologic?
Analysts are divided on their view about Hologic share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hologic is a Sell and believe this share price will drop from its current level to $60.00.
-
What Is Hologic's Price Target?
The price target for Hologic over the next 1-year time period is forecast to be $67.96 according to 15 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 13 analysts rate the stock a Hold.
-
Is HOLX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hologic is a Hold. 13 of 15 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HOLX?
You can purchase shares of Hologic via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hologic shares.
-
What Is The Hologic Share Price Today?
Hologic was last trading at $56.21 per share. This represents the most recent stock quote for Hologic. Yesterday, Hologic closed at $55.43 per share.
-
How To Buy Hologic Stock Online?
In order to purchase Hologic stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
